The purpose of this study is to establish the clinical effectiveness of antidepressants by
pharmacogenomic approach, and to determine the levels of inflammatory factors between the
baseline and the end point of the study in Taiwanese major depressive disorder (MDD)
patients.
Phase:
Phase 4
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborator:
Department of Health, Executive Yuan, R.O.C. (Taiwan)